SCI Pharmtech, Inc (4119) Fair Value & Analysis

Healthcare · TW · Market cap 5.9B TWD

Below-average quality, and screening another 71% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (19.85 TWD). The favourable scenario is already priced in.
• Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.

How to read this chart

60‑month range 40.40 TWD – 115.66 TWD · fair‑value band 11.46 TWD – 19.85 TWD · the 52.50 TWD price screens above the 15.27 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

SCI Pharmtech, Inc (4119) currently trades at 52.50 TWD, while our model-based Fair Value estimate is 15.27 TWD, implying the stock looks roughly 70.9% overvalued today. The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, SCI Pharmtech, Inc generated revenue of 1.4B TWD at a net margin of 7.0%. Revenue grew 4.3% year over year. It earns a return on equity of 1.8%. Net debt stands at 927M TWD. Fundamentals as of Jul 23, 2026

Our scenario range runs from 11.46 TWD (bear case) to 19.85 TWD (bull case); at 52.50 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 23% below its 52-week high and 33% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -71%, 4119 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Asset-Based (30.24 TWD) versus Earnings-Based (6.93 TWD). Highest evidence: Residual Income (76).

Key figures & financial health

Quality Score breakdown

About the company

SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals.

Full company description

SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofen sodium, methylphenidate HCl, pentobarbital sodium, pimobendan, probucol, propafenone HCI, sodium valproate, thiopental, and valproic acid; and develops benserazide, CBN, and CBDv. It also provides intermediate products, such as diethyl isobutyl malonate, benzhydrylamine, 1-Benzhydrylazetidin-3-ol, azetidin-3-ol hydrogenchloride, 1-(2-hydroxyphenyl)-3-phenylpropan-1-one, ritalinic acid, d-ritalinic acid HCl, pyrogallol aldehyde, menthadienol, 5-pentylbenzene-1,3-diol olivetol, methyl 2,4-dihydroxy-6-pentylbenzoate, ethyl 2,4-dihydroxy-6-pentylbenzoate ethyl olivetolate, divarinol, lisdexamfetamine intermediate, UDP-GIcNAz, and UDP-GaINAz. In addition, the company offers customized production services. It operates in Italy, Spain, the Netherlands, Belgium, the United States, Japan, Germany, Taiwan, Switzerland, and internationally. SCI Pharmtech, Inc. was incorporated in 1987 and is based in Taoyuan City, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

SCI Pharmtech, Inc reported revenue of 1.3B TWD in FY2025 versus 864M TWD in FY2021, a compound +11.7%/yr. Reported net income was 107M TWD in FY2025, compounding +17.8%/yr from FY2021.

4119 screens 71% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 623 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.